EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 334 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR How Therapy Helped Me Cope During Cancer: A Survivor’s Perspective October 24, 2023 More Than One in 10 Patients With Lung Cancer Do Not... March 17, 2021 Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... June 2, 2021 Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 Load more HOT NEWS Cómo mantenerse seguro e independiente durante el tratamiento contra el cáncer Sing Anyway Crazy Bride Called Off Her Wedding Because Her Guests Refused To... FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients
